المؤلفون: Sarıgül Yıldırım, Figen, Candevir, Aslıhan, Akhan, Sıla, Kaya, Selçuk, Çabalak, Mehmet, Alkan, Sevil

مصطلحات موضوعية: Antiretroviral, ART, HIV, Rapid start

الوصف: Background: Rapid initiation of antiretroviral therapy (ART) reduces the transmission of HIV infection in the community. This study aimed to determine whether rapid ART initiation is effective compared to standard ART treatment in our country. Methods: Patients were grouped based on time to treatment initiation. HIV RNA levels, CD+4 T cell count, CD4/CD8 ratio, and ART regimens were recorded at baseline and follow-up visits for 12 months. Results: There were 368-ART naive adults (treatment initiated at the time of HIV diagnosis; 143 on the first day, 48 on the secondseventh day, and 177 after the seventh day). Although virological suppression rates at 12th months were higher in all groups, over 90% on average, there were no statistically significant differences in HIV-1 RNA suppression rates, CD+4 T cell count, and CD4/CD8 ratio normalization in the studied months but in multivariate logistic regression analysis; showed a significant correlation between both virological and immunological response and those with CD4+ T <350 cells/mL at 12th month in total patients. Conclusion: Our findings support the broader application of recommendations for rapid ART initiation in HIV patients.

وصف الملف: application/pdf

العلاقة: International Journal of General Medicine; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Yıldırım, F. S., Candevir, A., Akhan, S., Kaya, S., Çabalak, M., Ersöz, G., … Çelen, M. K. (2023). Rapid initiation of antiretroviral therapy. International Journal of General Medicine, 16, 1867–1877. https://doi.org/10.2147/IJGM.S393370Test; https://doi.org/10.2147/IJGM.S393370Test; https://hdl.handle.net/20.500.12428/5420Test; 16; 1867; 1877; Q3; WOS:000994365300001; 2-s2.0-85160296181; PMID: 37213471

الإتاحة: https://doi.org/10.2147/IJGM.S393370Test
https://doi.org/20.500.12428/5420Test
https://hdl.handle.net/20.500.12428/5420Test

المؤلفون: Durusu Tanriover, Mine, Altuntas Aydin, Ozlem, Guner, Rahmet, Yildiz, Orhan, Celik, Ilhami, Kose, Sukran, Akhan, Sila, Akalin, Emin Halis, Ozdarendeli, Aykut, Unal, Serhat, Ates, Ihsan, Kara, Ates

المصدر: Hum Vaccin Immunother ; ISSN:2164-554X ; Volume:20 ; Issue:1

مصطلحات موضوعية: COVID-19, CoronaVac, TURKOVAC, adverse events, inactive COVID-19 vaccine, previous infection, safety

الوصف: This study- a secondary analysis of data from a randomized, observer-blinded, non-inferiority study among volunteers between 18-55 y old in Türkiye- evaluated the impact of previous SARS-CoV-2 infection before the first dose of inactive TURKOVAC on post-vaccine local and systemic adverse events (AEs) comparing with CoronaVac. Of 1266 participants analyzed, 27.7% had a previous COVID-19 history. Local and systemic AEs were observed in 37.3% and 39% of the participants. The frequency of AEs was slightly higher in the first 30 minutes and 24 hours among participants with a COVID-19 history; none were severe. 1203 participants had a second dose vaccination, and 27.3% had a history of COVID-19. The frequencies of local and systemic AEs after the second dose were similar between those with and without a COVID-19 history. The TURKOVAC and CoronaVac showed similar frequencies of local and systemic AEs in the first 30 minutes after vaccination.

العلاقة: https://doi.org/10.1080/21645515.2024.2346388Test; https://pubmed.ncbi.nlm.nih.gov/38924774Test

الإتاحة: https://doi.org/10.1080/21645515.2024.2346388Test
https://pubmed.ncbi.nlm.nih.gov/38924774Test

المؤلفون: SAYAN, MURAT, TOYGAR DENİZ, MÜGE, Tamer, Gulden Sonmez, AKHAN, SILA, AZAK KARALİ, EMEL

الوصف: Objectives: Recently, with the use of direct-acting antivirals (DAA) for treating chronic hepatitis C (CHC), the success rate has exceeded 90%. The implementation of these strong therapies has reduced the role of monitoring therapy with hepatitis C virus (HCV)-RNA tests. The current study compares the HCV-core antigen test (HCV-Ag) with HCV-RNA in terms of correlation, effectiveness and cost in patients who started DAA and to evaluate the usability of HCV-Ag as a routine laboratory test.

العلاقة: 77496c49-4cc7-4f4d-8277-f0443e971151; https://avesis.kocaeli.edu.tr/publication/details/77496c49-4cc7-4f4d-8277-f0443e971151/oaiTest

الإتاحة: https://doi.org/10.4274/vhd.galenos.2022.2021-3-2Test
https://avesis.kocaeli.edu.tr/publication/details/77496c49-4cc7-4f4d-8277-f0443e971151/oaiTest

المؤلفون: ÖZDARENDELİ, AYKUT, AKALIN, EMİN HALİS, AKHAN, SILA, Kose, Sukran, Doganay, Hamdi Levent, Celik, Ilhami, YILDIZ, ORHAN, Guner, Rahmet, Aydin, Ozlem Altuntas, DURUSU TANRIÖVER, MİNE, ÜNAL, SERHAT, SEZER, ZAFER

الوصف: We present the interim results of the efficacy, immunogenicity, and safety of the two-dose schedules of TURKOVAC versus CoronaVac. This was a randomized, observer-blinded, non-inferiority trial (NCT04942405). Volunteers were 18-55 years old and randomized at a 1:1 ratio to receive either TURKOVAC or CoronaVac at Day 0 and Day 28, both of which are 3 mu g/0.5 mL of inactivated severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) adsorbed to aluminum hydroxide. The primary efficacy outcome was the prevention of polymerase chain reaction (PCR)confirmed symptomatic coronavirus disease 2019 (COVID-19) at least 14 days after the second dose in the modified per-protocol (mPP) group. Safety analyses were performed in the modified intention-to-treat (mITT) group. Between 22 June 2021 and 7 January 2022, 1290 participants were randomized. The mITT group consisted of 915 participants, and the mPP group consisted of 732 participants. During a median follow-up of 90 (IQR 86-90) days, the relative risk reduction with TURKOVAC compared to CoronaVac was 41.03% (95% CI 12.95-60.06) for preventing PCR-confirmed symptomatic COVID-19. The incidences of adverse events (AEs) overall were 58.8% in TURKOVAC and 49.7% in CoronaVac arms (p = 0.006), with no fatalities or grade four AEs. TURKOVAC was non-inferior to CoronaVac in terms of efficacy and demonstrated a good safety and tolerability profile.

العلاقة: a283bd9f-b4e6-465e-9d5a-066aa0c228f9; https://avesis.hacettepe.edu.tr/publication/details/a283bd9f-b4e6-465e-9d5a-066aa0c228f9/oaiTest

الإتاحة: https://doi.org/10.3390/vaccines10111865Test
https://avesis.hacettepe.edu.tr/publication/details/a283bd9f-b4e6-465e-9d5a-066aa0c228f9/oaiTest

المؤلفون: Doganay, Hamdi Levent, Tanriover, Mine Durusu, Akova, Murat, Guner, Hatice Rahmet, Azap, Alpay, Akhan, Sila, Kose, Sukran

الوصف: Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. Methods This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 mu g inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0.5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. Findings Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65.1%] in the vaccine group and 3568 [34.9%] in the placebo group) and the per protocol group consisted of 10 029 ...

العلاقة: Lancet; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://hdl.handle.net/11454/76920Test; https://doi.org/10.1016/S0140-6736Test(21)01429-X; Aksu, Kurtuluş/0000-0001-6195-1158; Cinar, Gule/0000-0002-7635-8848; yavuz, serap şimşek/0000-0002-4675-169X; kilinc toker, aysin/0000-0002-6775-1234; Yıldırmak, Mustafa Taner/0000-0001-7006-7161; Korten, VolkanO/0000-0002-9991-814X; Ozkul, Aykut/0000-0001-5008-9443; 398; 10296; 213; 222

الإتاحة: https://doi.org/10.1016/S0140-6736Test(21)01429-X
https://hdl.handle.net/11454/76920Test

المؤلفون: Tanriover, Mine Durusu, Doganay, Hamdi Levent, Akova, Murat, Guner, Hatice Rahmet, Azap, Alpay, Akhan, Sila, Kose, Sukran

الوصف: Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey. Methods This was a double-blind, randomised, placebo-controlled phase 3 trial. Volunteers aged 18-59 years with no history of COVID-19 and with negative PCR and antibody test results for SARS-CoV-2 were enrolled at 24 centres in Turkey. Exclusion criteria included (but were not limited to) immunosuppressive therapy (including steroids) within the past 6 months, bleeding disorders, asplenia, and receipt of any blood products or immunoglobulins within the past 3 months. The K1 cohort consisted of health-care workers (randomised in a 1:1 ratio), and individuals other than health-care workers were also recruited into the K2 cohort (randomised in a 2:1 ratio) using an interactive web response system. The study vaccine was 3 mu g inactivated SARS-CoV-2 virion adsorbed to aluminium hydroxide in a 0.5 mL aqueous suspension. Participants received either vaccine or placebo (consisting of all vaccine components except inactivated virus) intramuscularly on days 0 and 14. The primary efficacy outcome was the prevention of PCR-confirmed symptomatic COVID-19 at least 14 days after the second dose in the per protocol population. Safety analyses were done in the intention-to-treat population. This study is registered with ClinicalTrials.gov (NCT04582344) and is active but no longer recruiting. Findings Among 11 303 volunteers screened between Sept 14, 2020, and Jan 5, 2021, 10 218 were randomly allocated. After exclusion of four participants from the vaccine group because of protocol deviations, the intention-to-treat group consisted of 10 214 participants (6646 [65.1%] in the vaccine group and 3568 [34.9%] in the placebo group) and the per protocol group consisted of 10 029 ...

العلاقة: Lancet; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; https://doi.org/10.1016/S0140-6736Test(21)01429-X; https://hdl.handle.net/11454/76920Test; 398; 10296; 213; 222; WOS:000674291900021; 2-s2.0-85110110235

الإتاحة: https://doi.org/10.1016/S0140-6736Test(21)01429-X
https://hdl.handle.net/11454/76920Test

المؤلفون: TAŞOVA, YEŞİM, Doganay, Hamdi Levent, Guner, Hatice Rahmet, Azap, Alpay, AKHAN, SILA, Kose, Sukran, Erdinc, Fatma Sebnem, AKALIN, EMİN HALİS, TABAK, Ömer Fehmi, PULLUKÇU, HÜSNÜ, Batum, Ozgur, Yavuz, Serap Simsek, TURHAN, ÖZGE, Yildirmak, Mustafa Taner, KÖKSAL, IFTAHAR, KORTEN, VOLKAN, YILMAZ, GÜRDAL, ÇELEN, MUSTAFA KEMAL, Altin, Sedat, Celik, Ilhami, BAYINDIR, YAŞAR, Karaoglan, Ilkay, Yilmaz, Aydin, ÖZKUL, AYKUT, Gur, Hazal, DURUSU TANRIÖVER, MİNE, AKOVA, MURAT, ÜNAL, SERHAT

الوصف: Background CoronaVac, an inactivated whole-virion SARS-CoV-2 vaccine, has been shown to be well tolerated with a good safety profile in individuals aged 18 years and older in phase 1/2 trials, and provided a good humoral response against SARS-CoV-2. We present the interim efficacy and safety results of a phase 3 clinical trial of CoronaVac in Turkey.

العلاقة: 9803421a-f9e2-4607-b4ae-438defeb215f; https://avesis.hacettepe.edu.tr/publication/details/9803421a-f9e2-4607-b4ae-438defeb215f/oaiTest

الإتاحة: https://doi.org/10.1016/s0140-6736Test(21)01429-x
https://avesis.hacettepe.edu.tr/publication/details/9803421a-f9e2-4607-b4ae-438defeb215f/oaiTest

المؤلفون: Demirtürk, Neşe, Aygen, Bilgehan, Çelik, İlhami, Mistik, Reşit, Akhan, Sıla, Barut, Şener, Ural, Onur, Batırel, Ayşe, Şimsek, Funda, Ersöz, Gülden, İnan, Dilara, Kınıklı, Sami, Türker, Nesrin, Bilgin, Hüseyin, Gürbüz, Yunus, Tülek, Necla, Tarakçı, Hüseyin, Yıldız, Orhan, Türkoğlu, Emine, Güzel, Deniz Kamalak, Şimsek, Sümeyra, Tuna, Nazan, Demir, Nazlım Aktuğ, Çağatay, Atahan, Çetinkaya, Rıza Aytaç, Karakeçili, Faruk, Hakyemez, İsmail Necati, Ertem, Günay Tuncer, Örmen, Bahar, Korkmaz, Pınar, Sili, Uluhan, Kuruüzüm, Ziya, Şener, Alper, Özel, Selcan Arslan, Öztürk, Sinan, Süer, Kaya, Çelen, Mustafa Kemal, Konya, Petek, Asan, Ali, Saltoğlu, Neşe, Doğan, Nurhan

مصطلحات موضوعية: Chronic hepatitis C, Sofosbuvir, Ledipasvir, Sustained virological response, Genotype, Real-world data

الوصف: WOS:000648816400007 ; PMID: 33960939 ; Background: In this study, we aimed to investigate the efficacy and safety of sofosbuvir-based therapies in the treatment of chronic hepatitis C in real-world clinical practice. Methods: Data from patients with chronic hepatitis C treated with SOF/LDV +/- RBV or SOF/RBV in 31 centers across Turkey between April 1, 2017, and August 31, 2018, were recorded in a nationwide database among infectious disease specialists. Demographics, clinical, and virological outcomes were analyzed. Results: A total of 552 patients were included in the study. The mean age of the patients was 51.28 +/- 14.2, and 293 (55.8%) were female. The majority had HCV genotype 1b infection (65%), 75.04% of the patients underwent treatment, and non-cirrhosis was present at baseline in 381 patients (72.6%). SOF/LDV +/- RBV treatment was given to 477 patients and 48 patients received SOF/RBV according to HCV genotype. The total SVR12 rate was 99% in all patients. Five patients experienced disease relapse during the study and all of them were genotype 2. In patients infected with HCV GT2, SVR12 was 77.3%. SVR was 100% in all patients infected with other HCV genotypes. All treatments were well tolerated by patients without causing severe adverse events. Side effects and side effects-associated treatment discontinuation rates were 28.2% and 0.4%, respectively. Weakness (13.7%) was the common side effect. Conclusion: The present real-world data of 525 patients with HCV genotypes 1, 1a, 1b, 3, 4, and 5 who underwent SOF/LDV +/- RBV treatment in Turkey demonstrated a high efficacy and safety profile. HCV GT2 patients should be treated with more efficacious treatment.

وصف الملف: application/pdf

العلاقة: Turkish Journal of Gastroenterology; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Demirtürk, N., Aygen, B., Çelik, İ., Mıstık, R., Akhan, S. ve Barut, S. (2021). Real-world data from Turkey: Is sofosbuvir/ledipasvir with or without ribavirin treatment for chronic Hepatitis C really effective?. Turkish Journal of Gastroenterology, 32(2), 155-163. https://doi.org/10.5152/tjg.2020.19569Test; https://www.turkjgastroenterol.org/en/real-world-data-from-turkey-is-sofosbuvir-ledipasvir-with-or-without-ribavirin-treatment-for-chronic-hepatitis-c-really-effective-136736Test; https://hdl.handle.net/11468/10264Test; 32; 155; 163; WOS:000648816400007; 2-s2.0-85106497950; https://search.trdizin.gov.tr/yayin/detay/511870Test; Q3; Q4

الإتاحة: https://doi.org/10.5152/tjg.2020.19569Test
https://hdl.handle.net/11468/10264Test
https://www.turkjgastroenterol.org/en/real-world-data-from-turkey-is-sofosbuvir-ledipasvir-with-or-without-ribavirin-treatment-for-chronic-hepatitis-c-really-effective-136736Test
https://search.trdizin.gov.tr/yayin/detay/511870Test

المؤلفون: Altunok, Elif Sargin, Sayan, Murat, Akhan, Sila, Aygen, Bilgehan, Yildiz, Orhan, Koruk, Suda Tekin, Mistik, Resit

المساهمون: Altunok, Elif Sargin, Sayan, Murat, Akhan, Sila, Aygen, Bilgehan, Yildiz, Orhan, Koruk, Suda Tekin, Mistik, Resit, Zonguldak Bülent Ecevit Üniversitesi

مصطلحات موضوعية: Baseline resistance, hepatitis C virus, mutation, protease inhibitors

الوصف: WOS: 000388326300001 ; PubMed: 27401586 ; Background: Drug resistance development is an expected problem during treatment with protease inhibitors (PIs), this is largely due to the fact that Pls are low-genetic barrier drugs. Resistance-associated variants (RAVs) however may also occur naturally, and prior to treatment with Pls, the clinical impact of this basal resistance remains unknown. In Turkey, there is yet to be an investigation into the hepatitis C (HCV) drug associated resistance to oral antivirals. Materials and methods: 178 antiviral-naive patients infected with HCV genotype 1 were selected from 27 clinical centers of various geographical regions in Turkey and included in the current study. The basal NS3 Pls resistance mutations of these patients were analyzed. Results: In 33 (18.5%) of the patients included in the study, at least one mutation pattern that can cause drug resistance was identified. The most frequently detected mutation pattern was T54S while R109K was the second most frequently detected. Following a more general examination of the patients studied, telaprevir (TVR) resistance in 27 patients (15.2%), boceprevir (BOC) resistance in 26 (14.6%) patients, simeprevir (SMV) resistance in 11 (6.2%) patients and faldaprevir resistance in 13 (7.3%) patients were detected. Our investigation also revealed that rebound developed in the presence of a Q80K mutation and amongst two V55A mutations following treatment with TVR, while no response to treatment was detected in a patient with a R55K mutation. Conclusion: We are of the opinion that drug resistance analyses can be beneficial and necessary in revealing which variants are responsible for pre-treatment natural resistance and which mutations are responsible for the viral breakthrough that may develop during the treatment. (C) 2016 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. ; Department of Scientific Research Project of Kocaeli University; Turkish Society of Clinic Microbiology and Infectious ...

العلاقة: INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; 50; https://dx.doi.org/10.1016/j.ijid.2016.07.003Test; https://hdl.handle.net/20.500.12628/3180Test

الإتاحة: https://doi.org/20.500.12628/318010.1016/j.ijid.2016.07.003Test
https://hdl.handle.net/20.500.12628/3180Test

المؤلفون: Sayan, Murat, Yildirim, Figen Sarigul, Akhan, Sila, Yildirim, Arzu Altuncekic, Sirin, Goktug, Cabalak, Mehmet, Demir, Mehmet, Can, Selver, Ersoz, Gulden, Altintas, Engin, Ensaroğlu, Fatih, Akbulut, Ayhan, Sener, Alper, Deveci, Aydin

المساهمون: İstinye Üniversitesi, Hastane, Fatih Ensaroğlu / 0000-0002-5474-8562, Ensaroğlu, Fatih, Fatih Ensaroğlu / EUA-5682-2022, Fatih Ensaroğlu / 37037277000

مصطلحات موضوعية: Hepatitis C, Hepatitis C Virus, Ns-5 Protein, Treatment Failure, Sequence Analysis

الوصف: Objectives: Chronic hepatitis C (CHC) is now a more curable disease with new direct acting antivirals (DAA). Although high sustained virologic response rates, failures still occur in DAA regimens. Our objective in this study was to characterize the real-life presence of clinically relevant resistance - associated substitutions (RASs) in the HCV NS5A gene in CHC patients whose DAA regimen has failed. Methods: The study enrolled 53 CHC patients who experienced failure with DAA regimen as the prospective longitudinal cohort between 2017-2019. Genotypic resistance testing was performed via the viral population sequencing method and The Geno2pheno HCV tool was used for RAS analysis. Results: The most frequent failure category was relapse (88%) followed by non-responder (12%). For a total of 36% of patients, RASs was detected in NS5A, Y93H was the most detected RAS in GT1b infected patients (89%). Conclusions: This study establishes an HCV failure registry for Turkey in which samples were combined with clinical, virologic and molecular data of adult patients whose DAA therapy failed. RASs can occur in CHC patients with DAA treatment failures. Evaluation of RAS after DAA failure is very important before retreatment is initiated to prevent virologic failure. (C) 2020 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. ; WOS:000540737100014 ; 32302766 ; Q2

وصف الملف: application/pdf

العلاقة: International Journal of Infectious Diseases; Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı; Sayan, M., Yildirim, F. S., Akhan, S., Yildirim, A. A., Sirin, G., Cabalak, M., … Deveci, A. (2020). NS5A resistance - associated substitutions in chronic hepatitis C patients with direct acting antiviral treatment failure in Turkey. INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 95, 84–89. https://doi.org/10.1016/j.ijid.2020.03.061Test; https://doi.org/10.1016/j.ijid.2020.03.061Test; https://hdl.handle.net/20.500.12713/398Test; 95; 84; 89

الإتاحة: https://doi.org/20.500.12713/398Test
https://doi.org/10.1016/j.ijid.2020.03.061Test
https://hdl.handle.net/20.500.12713/398Test